CADTH Canadian Drug Expert Committee final recommendation: Ticagrelor (Brilinta -- AstraZeneca Canada Inc.) indication : secondary prevention of atherothrombotic events
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ticagrelor be reimbursed when co-administered with low-dose (75 mg to 150 mg) acetylsalicylic acid (ASA) for the secondary prevention of atherothrombotic events in patients with a history (occurred at least one year ago) of myocardial i...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, August 25, 2016
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ticagrelor be reimbursed when co-administered with low-dose (75 mg to 150 mg) acetylsalicylic acid (ASA) for the secondary prevention of atherothrombotic events in patients with a history (occurred at least one year ago) of myocardial infarction (MI) and a high risk of developing an atherothrombotic event, with the following condition and criteria |
|---|---|
| Physical Description: | 1 PDF file (5 pages) |